On February 10, 2021, Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, announced a $130 million Series B financing from leading life sciences investors. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.

Day One is a purpose-built company committed to advancing important new cancer treatments for patients of all ages, with a focus on children. Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the company's lead program, DAY101. With the completion of the Series B financing, Day One has raised more than $190 million from leading life science investors since the company initiated operations in late 2019. 

The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

The Wilson Sonsini team that advised Day One on IP matters related to the transaction includes Maya Skubatch, Julia Minitti, and Ying Chen.

For more information, please see Day One’s press release.